- Redx Pharma said it had presented pre-clinical data at a US conference for a new drug development candidate to treat idiopathic pulmonary fibrosis, a long condition.

Data on candidate RXC006 was made public for the first time at the Advances in Fibrosis Drug Discovery Conference in Cambridge.

Head of fybrosis Peter Bunyard presented results that showed that RXC006 was able to suppress lung fibrosis.

Suppression of fibrosis had also been shown in animal models of both liver and kidney fibrosis.

'The data suggests that RXC006 has great potential to treat fibrosis in human patients,' chief scientific officer Richard Armer said.

'Redx are progressing RXC006 towards the clinic for the treatment of Idiopathic Pulmonary Fibrosis and plan to initiate first in man clinical trials during 2020.'

At 9:17am: [LON:REDX] Redx Pharma Plc share price was +0.7p at 7.85p

Story provided by